Physician

Perminder Bhatia, MD

According to 2025 Medicare claims, Perminder Bhatia, MD (NPI: 1013002328) practices neurology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is NEURO-PAIN MEDICAL CENTER INC (NPI: 1568687424; TIN: 770586745) and primary practice location at 93710-5473.

Bhatia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,561 traditional Medicare patients, billed 84,614 HCPCS/CPT codes, and received $814,807 in Medicare payments. The top billing code was 95819 (Measurement of brain wave activity (eeg), awake and asleep). Part D data shows 6,167 prescription claims across 1,020 beneficiaries totaling $3,831,453 in drug costs, led by Octagam (Immun Globg(Igg)/Malt/Iga Ov50). DME data shows 16 claims. Open Payments data shows 426 records totaling $1,203,341. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $404,076 to $814,807. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,640,472 to $3,831,453. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $21,137 to $4,195.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,122	6,793	$404,076
2016	1,088	5,618	$321,250
2017	1,168	6,075	$306,754
2018	1,244	5,546	$336,326
2019	1,368	7,620	$366,582
2020	1,434	8,067	$381,320
2021	1,564	6,864	$503,767
2022	1,541	6,842	$536,020
2023	1,604	7,528	$627,202
2024	1,561	84,614	$814,807

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	683	6,798	$2,640,472
2016	593	5,792	$2,587,823
2017	515	4,871	$2,885,531
2018	604	5,238	$2,565,151
2019	689	5,371	$2,234,695
2020	768	6,225	$3,221,429
2021	865	7,034	$5,544,444
2022	888	6,218	$6,120,922
2023	950	5,596	$4,062,721
2024	1,020	6,167	$3,831,453

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$1,784
2016	N/R	24	$67,324
2017	N/R	13	$61,411
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	16	$662

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
95819	Measurement of brain wave activity (eeg), awake and asleep	336	337	$377
95957	Measurement of brain wave activity (eeg), digital analysis	319	320	$244
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	935	1,837	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	343	461	$68
99426	Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month	353	535	$42

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	22	602	$548,042
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	27	382	$479,450
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	41	1,029	$294,398
Ingrezza	Valbenazine Tosylate	26	780	$217,070
Rexulti	Brexpiprazole	85	2,827	$153,576

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0849	Traction equipment, cervical, free-standing stand/frame, pneumatic, applying traction force to other than mandible	Y	N/R	16	$662

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	302	$76,195	Teva Pharmaceuticals USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	124	$1,127,147	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Perminder Bhatia, MD?

Tedicare shows public-source Medicare data for Perminder Bhatia, MD (NPI 1013002328), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Perminder Bhatia, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Perminder Bhatia, MD?

Perminder Bhatia, MD is linked to NEURO-PAIN MEDICAL CENTER INC (billing NPI 1568687424) in the available physician profile data.

Does Perminder Bhatia, MD have Open Payments data?

Perminder Bhatia, MD has 426 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.